DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Clinical trials for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DLBCL - DIFFUSE LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a tweak in Pre-Chemo boost CAR t success against tough lymphoma?
Disease control Recruiting nowThis early-phase study aims to find the safest and most effective way to prepare the body before CAR T cell therapy for diffuse large B-cell lymphoma (DLBCL). Researchers are testing different doses of chemotherapy drugs (fludarabine and cyclophosphamide) with or without low-dose…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 17, 2026 06:52 UTC
-
New combo targets hard-to-treat lymphoma mutations
Disease control Recruiting nowThis study tests whether adding the oral drug zanubrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of lymphoma (DLBCL) that has certain gene changes. About 21 adults with these mutations will receive the combination. The goal is to see if more patients…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated May 17, 2026 06:49 UTC
-
Engineered immune cells take on tough lymphoma
Disease control Recruiting nowThis study tests a new treatment for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, which are genetically modified to recognize and attack cancer cells. The go…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated May 17, 2026 06:48 UTC
-
New CAR T-Cell therapy aims to tackle tough lymphoma
Disease control Recruiting nowThis early-stage study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells. T…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated May 17, 2026 06:47 UTC
-
New hope for hard-to-treat lymphoma? early trial of LTZ-301 begins
Disease control Recruiting nowThis early-phase study tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: LTZ Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Double attack on lymphoma: CAR-T cells followed by antibodies show promise
Disease control Recruiting nowThis study tests whether giving an extra antibody drug (mosunetuzumab or glofitamab) after standard CAR-T cell therapy can improve outcomes for people with aggressive large B-cell lymphoma that has returned or not responded to prior treatments. About 42 participants will receive …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for tough lymphomas: experimental drug MDX2003 enters human testing
Disease control Recruiting nowThis study tests an experimental drug called MDX2003 in about 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or not improved after at least two prior treatments. The main goals are to find the safest dose and to see…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New triple therapy offers hope for hard-to-treat lymphoma patients
Disease control Recruiting nowThis study tests a combination of three drugs (pirtobrutinib, lisaftoclax, and rituximab) in 29 adults with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment. The goal is to see if this combination can shrink or eliminate tumors. Pa…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New cell therapy aims to shrink stubborn lymphomas
Disease control Recruiting nowThis early study tests a new treatment called CT1182 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other therapies. About 24 participants will receive the treatment to see if it is safe and can shrink tumors. The goal is to find the best dose …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
New hope for chinese lymphoma patients: glofitamab trial launched
Disease control Recruiting nowThis study tests a drug called glofitamab in 20 Chinese patients with a type of blood cancer (diffuse large B-cell lymphoma) that has come back or not responded to at least two prior treatments. The goal is to see if the drug can control the cancer and how safe it is. Participant…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Heart-Saving shield for lymphoma patients under study
Prevention Recruiting nowThis study tests whether the drug dexrazoxane can prevent permanent heart damage caused by chemotherapy in people with diffuse large B-cell lymphoma (DLBCL). About 324 adults with untreated DLBCL will receive either standard chemo plus dexrazoxane or standard chemo alone. The goa…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Prevention
Last updated May 06, 2026 16:01 UTC
-
Can a chat tool help doctors talk better about lymphoma?
Knowledge-focused Recruiting nowThis study is developing and testing a communication training program called Hematolo-GIST for doctors who treat large B-cell lymphoma. The goal is to help doctors talk with patients about their diagnosis and plan future care. About 48 people (doctors and patients) will take part…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 07:00 UTC
-
Spinal fluid test may spot hidden brain relapse risk in lymphoma patients
Knowledge-focused Recruiting nowThis study looks at whether a new test on spinal fluid can find signs of lymphoma in the brain earlier than standard methods. It involves 50 people with aggressive B-cell lymphoma who are at high risk for the cancer spreading to the central nervous system. Researchers will track …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 06:59 UTC